https://www.selleckchem.com/pr....oducts/stat3-in-1.ht
We tested the production of two proprietary IgG1 mAbs in the engineered host cells, and found that the titers were comparable to CHOZN® cells. The mAbs generated from either KO cell line exhibited loss of fucose modification, leading to significantly boosted FcγRIIIa binding and ADCC effects. Our data demonstrated that both FX-/- and Gmds-/- host cells could replace Fut8-/- CHO cells for clinical manufacturing of antibody therapeutics.Selective androgen receptor modulators (SARMs) are compounds with specific androgenic properties inv
Like
Comment
Share
